Search Results

Investigating the landscape of US orphan product approvals.

• Authors : Miller, Kathleen L.; Lanthier, Michael

• Source: Orphanet Journal of Rare Diseases. October 22, 2018, Vol. 13 Issue 1.

Record details

Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.

• Authors : Divino, Victoria; DeKoven, Mitch; Kleinrock, Michael

• Source: Orphanet Journal of Rare Diseases. May 21, 2016, Vol. 11 Issue 68.

Record details

Push to cure rare diseases; FDA officials go to new lengths to encourage applications for orphan-drug status.

• Authors : Marcus, Amy Dockser

• Source: The Wall Street Journal Eastern Edition. 2010, Vol. 0, Issue 0, pages. 1

Record details

The Orphan Drug Act has been a huge success.

• Authors : Rensi, Ed

• Source: The Wall Street Journal Eastern Edition. 2008, Vol. 0, Issue 0, pages. 1

Record details

Tax code overhaul proposes to cut credits for developing orphan drugs

• Source: Adverse Event Reporting News. March 18, 2014, Vol. 11 Issue 6, p17, 2 p.

Record details

Incentives for orphan drug research and development in the United States.

• Authors : Seoane-Vazquez, Enrique; Rodriguez-Monguio, Rosa; Szeinbach, Sheryl L.

• Source: Orphanet Journal of Rare Diseases. December 16, 2008, Vol. 333.

Record details

Canada should follow the U.S. example on 'orphan' diseases

• Authors : Picard, Andre

• Source: Globe & Mail (Toronto, Canada). July 17, 2008, L4

Record details